Martin G. Sanda, MD

Martin G Sanda, MDProfessor and Chairman of Urology

Clinical Practice Sites

Emory University Hospital
(404) 778-6874

Emory Saint Joseph's Hospital
(404) 778-8376

Undergraduate Education

BA Molecular Biophysics and Biochemistry
Yale University – Cum Laude (1979-1983)

Medical School

Columbia University, New York, NY (1983-1987)

Surgery Residency

Medical College of Virginia, Richmond, VA (1987-1989)

Urology Residency

Johns Hopkins Hospital (1991-1995)


Surgical Oncology & Immunology Fellowship
National Institute of Health, Bethesda, MD (1989-1991)

Board Certification

American Board of Urology (1997)

Clinical and Academic Appointments

The Johns Hopkins University (1995)
University of Michigan (1995-2003)
University of Michigan Cancer Center (1999-2003)
Beth Israel Deaconess Medical Center (2004-2013)
Dana Farber/Harvard Cancer Center (2007-2013)
Harvard Medical School (2004-2013)
Emory University School of Medicine (2013-current)

Primary Clinical Interests

Prostate Cancer
Bladder Cancer
Elevated PSA

All Areas of Clinical Interest

prostate cancer
robotic surgery
bladder cancer
testis cancer
urinary diversion

Year Started Practice:


Year Started at Emory:


See full curriculum vitae

About Dr. Sanda

In February of 2013, Martin G. Sanda, MD, an internationally recognized prostate cancer surgeon and scientist, was appointed Chair of the Department of Urology at Emory University School of Medicine and service chief for Emory Healthcare. In that capacity, he will also serve as Director of the Prostate Cancer Center, which will be established within Emory’s Winship Cancer Institute.

Sanda joins Emory from Harvard Medical School, where he was Professor of Surgery in urology, and from Beth Israel Deaconess Medical Center, where he served as Director of the Prostate Cancer Center. He was also the co-leader of the Prostate Cancer Program at the Dana Farber Cancer Center.

Sanda is principal investigator of three multi-center consortium studies funded by the National Cancer Institute and the Prostate Cancer Foundation that seek to develop urine tests for detecting prostate cancer; to develop benchmarks for improving quality of life among cancer survivors; and to develop innovative prostate cancer vaccines. These studies have enrolled over 4,400 patients with findings published in leading medical journals including the Journal of the American Medical Association and the New England Journal of Medicine.

Sanda’s clinical practice, which includes robotic prostatectomy and robotic cystectomy, is focused on developing new surgical and non-surgical approaches to cancer care and to improving the quality of life among cancer survivors.After receiving his BA in molecular biophysics and biochemistry from Yale University cum laude in 1983, Sanda went on to receive his MD degree at Columbia University in 1987. He then trained as a general surgery resident at the Medical College of Virginia and as a surgical oncology fellow at the National Cancer Institute. He completed his urology residency at Johns Hopkins Hospital.

Sanda has served as Chair of the Prostate and Genito-Urinary Collaborative Group of the National Cancer Institute’s Early Detection Research Network (2007-2010), has spearheaded two nationwide, NCI Cooperative Group prostate cancer clinical trials, has served on numerous federal funding review panels, and has served on the Research Council of the American Urological Association since 2011. Sanda has more than 150 peer-reviewed publications, and his work has been cited more than 5,000 times in biomedical literature.

Honors & Awards

J. Hartwell Harrison Memorial Resident Education Award (2012)
Harvard-Longwood Urology Residency

Visiting Professor (2012)
Memorial Sloan Kettering Cancer Center

Honorary Degree: Master of Arts (2011)
Harvard University

Service Recognition Award for 3-year term as Chair, EDRN Prostate/GU Collaborative Group (2010)
National Cancer Institute

Leadership Development for Physicians at Academic Health Centers
(Select Course at Harvard School of Public Health) (2010)
Nominated by Senior Leadership at BIDMC

Visiting Professor, Urology (2010)
Division of Urology, University of Chicago

Best of Boston - Top Doctors (Urology) (2005-2012)
Boston Magazine

Society of Urological Oncology Young Investigator Award (2005)
Society of Urological Oncology

Best Doctors in America: Best in Michigan (2003-2004)
Best in Massachusetts (2005-2012)
Castle-Connolly: National peer survey

Outstanding Achievement Award (2001)
University of Michigan Urology Resident

Society for Basic Urologic Research Young Investigator Award (1999)
Society for Basic Urologic Research

Pfizer Scholars in Urology Award (1998)
American Foundation of Urological Disease

European Association of Urology Traveling Fellowship (1998)
American Urological Association

Clinical Research Prize Second Place.
"Genetic Susceptibility of Benign Prostatic Hyperplasia" (1994)
American Urological Association

CaPCure Award, Second Place.
"Gene Therapy for Human Prostate Cancer" (1994)
American Urological Association

Basic Science Research Prize, Second Place
"Human Prostate Cancer Cells are Suitable Targets for Gene-Modified Immunotherapy" (1993)
American Urological Association

Sandoz Award for Excellence in Medical Research:
"IL-2 Inhibition by a Gly-Pro Affinity Column Eluate" (1987)
Columbia University College of Physicians & Surgeons


Barth RJ, Mule JJ, Asher AL, Sanda MG, and SA Rosenberg.  Identification of unique murine tumor-associated antigens by tumor-infiltrating lymphocytes using tumor-specific secretion of interferon-gamma and tumor necrosis factor.  J IMMUNOL METH  1991;140: 269-79.

Sanda MG, Bolton E, Mule JJ, and SA Rosenberg.  In vivo administration of recombinant Macrophage-Colony Stimulating Factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells.  J IMMUNOTHER  1992; 12:132-7.

Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort R, de Smet MD, Schwartzentruber DJ, White DE, Lotze MT, and SA Rosenberg.  Intravenous administration of recombinant human Macrophage Colony-Stimulating Factor to patients with metastatic cancer: A phase I study. J CLIN ONCOLOGY 1992;10:1643-9.

Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Dranoff G, Cohen LK, Pardoll DM, Mulligan RC and Simons JW. Demonstration of a rational strategy for human prostate cancer gene therapy.  J UROL 1994; 151: 622-8.

Sanda MG, Beaty TH, Stutzman R, Childs B and Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J UROL 1994;152:115-9.

Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW, Balkissoon J, Fenton RM, DeBarge LR, Kaye J, Rosenberg SA and Parkinson DR.  Phase I trial of recombinant human M-CSF administered by continuous intravenous infusion in patients with metastatic cancer. J NATL CANCER INST 1994; 86:39-45.

Partin AW, Page WF, Lee BR, Sanda MG, Miller RN and Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. UROLOGY 1994; 44: 646-50.

Sanda MG and Simons JW. Gene therapy for urological cancer. UROLOGY 1994; 44:617-24.

Moore RG, DeMaree RD, Sanda MG and Kavoussi LR.  Retroperitoneoscopy: effects of insufflation media on surrounding tissue during balloon rupture. J ENDOUROL 1995; 9: 67-71.

Sanda MG, Restifo NP, Walsh J, Pardoll DM, and Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. J NATL CANCER INST 1995; 87: 280-285 (see comments pp 241-3).

Carducci MA, Ayyagari SR, Sanda MG and Simons JW. Gene therapy for human prostate cancer: translational research in the hormone refractory Dunning prostate model. CANCER 1995; 75: 2013-20.

Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, and Simons JW. Selection of men at high risk for recurrence for experimental adjuvant therapy following radical prostatectomy. UROLOGY 1995; 45: 831-8.

Sanda MG, Jeffs RD, and Gearhart JP.  Evolution of outcomes with the ileal hydraulic valve continent diversion: re-evaluation of the Benchekroun catheterizable stoma. WORLD J UROL 1996; 14:108-11.

Doehring CB, Sanda MG, Partin AW, Sauvageot J, Juo H, Beaty TH, Epstein JI, Hill G, and Walsh PC. Histopathologic characterization of hereditary benign prostatic hyperplasia. UROLOGY 1996; 48:650-3.

Sanda MG, Doehring CB, Binkowitz B, Beaty TH , Partin AW, Stoner E, and Walsh PC. Clinical and biological characteristics of familial benign prostatic hyperplasia. J UROL 1997; 157: 876-879.

Sanda MG. Biological principals and clinical development of prostate cancer gene therapy. SEMINARS IN UROLOGIC ONCOLOGY 1997;15: 43-55.

Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Zeng Z, Greenberg NM, and Sanda MG. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.  J UROLOGY 1998; 160:1500-5.

Sanda MG, Smith D, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE.  Recombinant vaccinia-PSA can induce a prostate-specific immune response in androgen-modulated human prostate cancer. UROLOGY 1999; 53: 260-6.

Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Imperiale M, Restifo NP, and Sanda MG. Generation and characterization of a novel vaccinia vector for recombinant vaccine therapy of tumors expressing SV40-T antigen. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999; 91: 169-75.

Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando, DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, and Nelson WG. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secret gm-csf using ex vivo gene transfer. CANCER RESEARCH 1999; 59: 5160-5168.

Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, and Sanda MG. Early castration reduces prostatic carcinogenesis in transgenic mice. UROLOGY 1999; 54:1112-1119.

Charles LG, Xie YC, Restifo NP, Roessler B, and Sanda MG. Pre-clinical efficacy of recombinant poxvirus immunization against Dunning rat prostate cancer in vivo. WORLD JOURNAL OF UROLOGY 2000; 18:(2) 136-142.

Rubin MA, Bassily N, Sanda MG, Montie J, Strawderman MS, and Wojno KJ. The relationship of greatest percent of biopsy core with cancer and perineural invasion in prostatic adenocarcinoma. AM J SURG PATH 2000; 24(2) 183-189.

Francis T and Sanda MG. Prospects and limitations of gene therapy for prostate and bladder cancers. CONTEMPORARY UROLOGY 2000; 12: 37-55.

Marcovich R, Wojno KJ, Wei JT, Rubin MA, Montie JE, and Sanda MG. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. UROLOGY 2000; 55(6): 904-8.

Hwang C and Sanda MG. Development of recombinant poxviruses for prostate cancer therapy. CURRENT OPINION IN MOLECULAR THERAPEUTICS 2000; 1(4): 471-479.

Tchetgen MB, Faerber G, Sanda MG, and Montie JE. Collagen injection for the treatment of ISD following cystectomy and orthotopic neobladder reconstruction in females. JOURNAL OF UROLOGY 2000;163:212-214.

Rubin MA, Mucci N, Shah R, Sanda MG, Wei JT, and Montie JE. Benign prostatic glands on surgical margins of radical prostatectomies: Frequency and associated risk factors. UROLOGY 2000; 56 (5): 721-725.

Wei JT, Dunn RL, Marcovich R, Montie, JE, and Sanda MG. Prospective assessment of patient-reported urinary continence following radical prostatectomy. JOURNAL OF UROLOGY 2000;164:744-748,.

Wei JT, Dunn RL, Litwin MS, Sandler HM, and Sanda MG. Development and validation of the Expanded Prostate Caner Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. UROLOGY 2000; 56(6): 899-905.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, and Marshall FF. Cancer cells engineered to secrete GM-CSF using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. CANCER CHEMOTHERAPY & PHARMACOLOGY 2000; 46:S67-72.

Dawson LA, Litzenberg DW, Brock KK, Sanda MG, Sullivan M, Sandler HM, and Balter, JM.  A comparison of ventilatory prostate movement in four treatment positions.  INT. J. RADIATION ONCOLOGY BIOL. PHYS 2000; 48(2): 319-323.

Rubin MA, Mucci NR, Manley S, Cushenberry E, Strawderman M, Sanda MG, Montie JE, and Bassily NH.  Predictors of gleason pattern 4/5 prostate cancer on radical prostatectomy:  Can high grade tumor be predicted preoperatively? JOURNAL OF UROLOGY 2001;165(1): 114-118.

Taj MM, Tawil RJ, Zeng Z, Hwang C, Sanda MG, and Wechsler DS. An Mxi1 adenovirus suppresses growth of DU145 human prostate cancer cells. PROSTATE 2001; 47: 194-204.

Sandler H. Shipley WU. Gomella L. Pienta K. Bard RH. Bruner D. Clark R. DeSilvio M. Gaspar L. Gillin M. Grignon D. Hammond E. Hanks G. Heydon KH. Kaufman DS. Lee WR. Michalski J. Mydlo J. Pisansky T. Pollack A. Porterfield H. Rifkin M. Roach M 3rd. Sanda M. True L. Vijayakumar S. Winter KA. Zeitman A. Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. INT J RADIAT ONCOL BIOL PHYS. 2001; 51(Suppl 2):28-38.

Rashid M, Sanda MG, Vallorosi C, Rios-Doria J, Rubin M, and Day M. Posttranslational truncation and inactivation of human E-Cadherin distinguishes prostate cancer from matched normal prostate. CANCER RESEARCH 2001; 61: 489-492.

Imperiale MJ, Pass HI, and Sanda MG. Prospects for an SV40 Vaccine. SEMINARS IN CANCER BIOLOGY 2001; 11(1): 81-5.

Kielb SJ, Shah NL, Rubin MA, and Sanda MG. Functional p53 mutation as a molecular determinant to paclitaxel and gemcitabine susceptibility in human bladder cancer. JOURNAL OF UROLOGY 2001; 166(2): 482-487.

Kielb S, Dunn R, Rashid M, Murray S, Montie J, Sanda MG, and Wei J.  Assessment of early continence recovery following radical prostatectomy: Patient-reported symptoms and impairment. JOURNAL OF UROLOGY 2001; 166(3): 958-961.

Nelson C, Rubin MA, Strawderman M, Montie JE, and Sanda MG. Pre-operative parameters for predicting early prostate cancer recurrence following radical prostatectomy. UROLOGY 2002; 59: 740-746; discussion 745-6.

Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, and Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual HRQOL outcome after prostate brachytherapy. UROLOGY 2002; 59(4):480-4.

Litzenberg DW, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, Lam KL, Brock KK and Balter JM: Daily prostate targeting using implanted radio-opaque markers. INT J RADIAT ONCOL BIOL PHYS. 2002; 52: 699-703.

Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, and Sanda MG. A comprehensive comparison of health related quality of life following contemporary therapies for localized prostate cancer. JOURNAL OF CLINICAL ONCOLOGY 2002; 20(2): 557-566.

Dash A, Sanda MG, Yu M, Taylor JMG, Fecko A, and Rubin MA. Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification UROLOGY 2002; 60(2):276-80.

Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. NATURE 2002; 419: 624 – 629.

Neeley CN, McDonagh KT, Overwijk WW, Restifo NP, and Sanda MG. Antigen-specific tumor vaccine efficacy against prostate cancer with low class I MHC requires competent class II MHC. THE PROSTATE 2002; 53:183-191.

Rubin MA, Zhou M, Dhanasekaran S, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, and Chinnaiyan AM. a-Methylacyl-CoA Racemase: a highly specific and sensitive marker for prostate cancer identified by DNA microarray analysis. JAMA 2002; 287:1662-1670.

Rao DS, Hyun TS, Mizukami IF, Rubin MA, Lucas PC, Sanda MG and Ross TS. Huntingtin Interacting Protein 1: a tumor marker of prostate cancer progression. J CLINICAL INVESTIGATION 2002; 110: 351-360.

Nelson C and Sanda MG. Contemporary diagnosis and management of angiomyolipoma. JOURNAL OF UROLOGY 2002; 168:1315-1325.

Tsien C, Griffith KA, Sandler HM, McLaughlin P, Sanda M, Montie J, Reddy S, Hayman JA Long term results of 3D conformal adjuvant and salvage radiotherapy following radical prostatectomy. UROLOGY, 2003; 62: 93-8.

Nelson CP, Dunn RL, Wei JT, Rubin MA, Montie JE, Sanda MG. Contemporary pre-operative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. UROLOGIC ONCOLOGY: Seminars and Original Investigations. 2003; 21: 213-218.

Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA and Day ML. Cleavage of E-cadherin and the role of an 80kDa fragment in the metastatic progression of prostate cancer. CLIN CANCER RES. 2003; 9: 6447-52.

Miller DC, Litwin MS, Sanda MG, Montie JE, Dunn RL, Resh J, Sandler H, and W ei JT. Use of quality indicators to evaluate localized prostate cancer care. CANCER 2003; 97:1428-35.

Rhodes D, Sanda MG, Otte AP, Chinnaiyan AM, and Rubin MA. Molecular markers for predicting biochemical recurrence in men with clinically localized prostate caner: a multiplex analysis using high-density tissue microarrays. JOURNAL OF THE NATIONAL CANCER INSTITUTE 2003; 95: 661-668.

Hollenbeck BK, Dunn RL, Wei JT, Montie JE, and Sanda MG. Determinants of long-term sexual HRQOL after radical prostatectomy measured by a validated instrument. JOURNAL OF UROLOGY 2003;169(4):1453-7.

Underwood W, Wei JT, Rubin MA, Resh J, Montie JE, and Sanda MG.  Underwood W 3rd, Wei J, Rubin MA, Montie JE, Resh J, Sanda MG. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. UROLOGIC ONCOLOGY 2004;22(1):20-4.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J NATL CANCER INST. 2004 96(11): 834-43. Erratum in: J Natl Cancer Inst. 2004 Jul 21;96(14):1112.

Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM.  Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. UROLOGY. 2004;63(5):946-50.

Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT.  Racial/ethnic disparities in the treatment of localized/regional prostate cancer. JOURNAL OF  UROLOGY 2004;171(4): 1504-7.

Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM.  Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. AMERICAN JOURNAL OF PATHOLOGY 2004 Mar;164(3):787-93.

Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA.  The role of metastasis-associated protein 1 in prostate cancer progression. CANCER RESEARCH 2004; 64(3):825-9. 

Dash A, Dunn RL, Resh J, Wei JT, Montie JE, Sanda MG. Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. UROLOGY 2004; 64(1):117-22.

Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG.  Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. CURRENT UROLOGY REPORTS 2004; 5(3): 212-9.

Shah NL, Sanda M. Health-related quality of life in treatment for prostate cancer: looking beyond survival. SUPPORT CANCER THER 2004 Jul 1;1(4):230-6. PubMed PMID: 18628147.

Miller, D, Sanda MG, Dunn RL et al.  Long-term outcomes among localized prostate cancer survivors: HRQOL changes 4 to 8 years following radical prostatectomy, external radiation and brachytherapy. JOURNAL OF CLINICAL ONCOLOGY 2005; 23(12):2772-80.

Bradley SV, Oravecz-Wilson KJ, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan A, Sanda MG, and Ross TS. Serum Antibodies to Huntingtin Interacting Protein-1: a new blood test for prostate cancer. CANCER RESEARCH 2005; 65(10):4126-33.

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. N ENGL J MED 2005; 353(12):1224-35.

Takegami M, Suzukamo Y, Sanda MG, Kamoto T, Namiki S, Arai Y, Ogawa O, Fukuhara S, Kakehi Y. [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)]. NIPPON HINYOKIKA GAKKAI ZASSHI. 2005 Nov; 96(7):657-69. Japanese. PubMed PMID: 16363651.

Hofer, MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG,

Gschwend JE, and Rubin MA.  Prognostic Factors in Lymph Node-Positive Prostate Cancer. UROLOGY 2006; 6 (5):1016-21.

Miller DC, Wei JT,  Dunn RL, Montie JE, Pimentel1 H, Sandler HM, McLaughlin PW, and Sanda MG. Utilization of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: the potential influence of sexual motivation and/or indifference. UROLOGY 2006; 68(1):166-71.

Montgomery JS, Gayed BA,  Hollenbeck BK, Daignault S, Sanda MG, Montie JE, Wei JT. Obesity adversely affects health related quality of life prior to and following radical retropubic prostatectomy. J UROLOGY 2006; 176(1):257-61; discussion 261-2.

Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. UROLOGY 2006; 68(6):1224-9.

Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA 2006; 296(19):2316-7.

Northouse LL, Mood DW, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Sanda MG, Kershaw T. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J CLIN ONCOL 2007; 25(27):4171-7.

Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. UROLOGY 2008;71(1):47-51.

Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. DRUG DESIGN, DEVELOPMENT AND THERAPY 2008; 2:17–24 (open access).

Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW.[-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation Study. J UROLOGY 2008 180(2):539-43

Mosquera JM, Perner S, Genega E, Sanda MG, Hofer M, Mertz K, Paris P, Simko J, Bismar T, Ayala G, Shah R, Loda M, Rubin M.  Characterization of  TMPRSS2-ERG Fusion High-grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. CLINICAL CANCER RESEARCH 2008; 14(11):3380-5.

Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy. PROSTATE 2008; 68(7):715-27.

Hollenbeck BK, Dunn RL, Wolf JS Jr, Sanda MG, Wood DP, Gilbert SM, Weizer AZ, Montie JE, Wei JT. Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery. QUAL LIFE RES  2008 17(6): 915-26.

Hu J, Hevelone N, Earle CC, Sanda MG, Lipsitz SR.  Patterns of care for radical prostatectomy in the United States from 2003-2005. J UROLOGY 2008; 180(5):1969-74

Haram KM, Peltier HJ, Lu B, Bhasin M, Out HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG,* Arredouani MS.* Gene expression profile of mouse prostate tumors reveals dysregulation in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.  PROSTATE, 2008; 68(14):1517-30.

Kershaw TS, Mood DW, Newth G, Ronis DL, Sanda MG, Vaishampayan U, Northouse LL. Longitudinal Analysis of a Model to Predict Quality of Life in Prostate Cancer Patients and their Spouses. ANN BEHAV MED 2008 36 (2):117-128.  Epub  2008 Sep 16.

Dandapani S and Sanda MG. Measuring health-related quality of life consequences from primary treatment for early stage prostate cancer. SEM RAD ONC 2008; 18(1):67-72.

Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda MG, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE. Phase II Trial of Paclitaxel, Carboplatin, and Gemcitabine in patients with Locally Advanced Carcinoma of the Bladder. J UROLOGY 2008 Dec;180(6):2384-8; discussion 2388. Epub 2008 Oct 18. PMID: 18930256

Ramachandran N,  Anderson KS, Raphael JV, Hainsworth E, Sibani S, Montor WR, Pacek M, Wong J, Eljanne M, Sanda MG, Hu YH, Logvinenko T, LaBaer J. Tracking humoral responses using self assembling protein microarrays. PROTEOMICS CLINICAL APPLICATIONS   2008 Oct; 2(10-11): 1518-1527.

Tseng-Rogenski S, Arredouani M, Neeley Y, Lu B, Chinnaiyan A, Sanda MG. Fas-mediated T cell deletion protentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. CANCER IMMUNOLOGY, AND IMMUNOTHERAPY 2008; 57(9):1357-65.

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. NEW ENGLAND JOURNAL OF MEDICINE 2008; 358(12):1250-61.

Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement. JOURNAL OF PROTEOME RESEARCH, 2009; 8 (1): 113-117. 

Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, and Sanda MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. DRUG DES DEVEL THER. 2009; 2:17-24. PubMed PMID: 19920890.

Sanda MG and Kaplan I.  Clinical Crossroads: Management of Early Stage Prostate Cancer JAMA 2009; 301(20):2141-51. Epub 2009 May 5. PMID: 19417179.

Shappley WV III, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG,* and  Chan JM* A prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.  J CLIN ONCOL 2009 Oct 20;27(30):4980-5. Epub 2009 Aug 31. PubMed PMID: 19720918.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega MG, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA,* and Sanda MG.*  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.  CLINICAL CANCER RESEARCH, 2009; 15(14):4706-11. Epub 2009 Jul 7. PMID: 19584163

Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V,

Rubin MA, Libermann TA, Sanda MG. Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer. CLIN CANCER RES. 2009 Sep 15;15(18):5794-802. Epub 2009 Sep 8. PMID: 19737960.

Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG. Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens by a Novel Assay Using Branched DNA. UROLOGY Nov; 74(5):1156-61. Epub 2009 Aug 3. PubMed PMID: 19647299; PubMed Central PMCID:  PMC2784207.

Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG. Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. JOURNAL OF UROLOGY, 2009 Dec;182(6):2653-8. PubMed PMID: 19836788.

Sandler HM, Liu P, Dunn RL, Khan DC, Tropper SE, Sanda MG, and Mantz CA. Reduction in patient-reported morbidity in prostate cancer patients treated with 81 gy IMRT using reduced PTV margins and electromagnetic tracking: assessing the impact of margin reduction (AIM) study. UROLOGY, 2010 May;75(5):1004-8. Epub 2010 Feb 13. PubMed PMID: 20153881.

Arredouani MS, Tseng-Rogenski S, Hollenbeck BK, Defeo-Jones D, Hwang C, and Sanda MG. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self antigen in transgenic mice. PROSTATE, 2010 Jun 15;70(9):1002-11. PubMed PMID: 20209643.

Katz MS, Efstathiou JA, D’Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL.  CaP calculator: An online decision support tool for clinically localized prostate cancer. BRIT J UROLOGY INTL, 2010 May; 105(10):1417-22. Epub 2010 Mar 15. PubMed PMID: 20346051.

Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, and Chan DW.  A prospective, multicenter, NCI EDRN study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. CANCER EPIDEMIOL BIOMARKERS PREV. 2010 May 19(5):1193-2000. PubMed PMID: 20447916; PubMed Central PMCID: PMC2867076.

Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE; PROSTQA Study Group. The experiences of unpartnered men with prostate cancer: a qualitative analysis. J CANCER SURVIV. 2011 Jun;5(2):132-41. doi: 10.1007/s11764-010-0157-3. Epub 2010 Nov 28. PubMed PMID: 21113818.

Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLOS ONE. 2010 Jun 25;5(6):e11311. PubMed PMID: 20593019; PubMed Central PMCID: PMC2892484.

Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, Litwin MS, Pavlovich CP. Comparison of validated instruments measuring sexual function in men. UROLOGY. 2010 Aug;76(2):380-6. Epub 2010 Jun 22. PubMed PMID: 20573377.

Kazer MW, Bailey DE, Sanda MG, Colberg, J, Kelly, WK. Internet Uncertainty Management Intervention for Older Men undergoing Active Surveillance for Prostate Cancer. ONCOLOGY NURSING FORUM. 2011 Sep;38(5):561-8. PubMed PMID: 21875843.

Szymanski KM, Wei JT, Dunn RL, and Sanda MG. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite Instrument (EPIC-26) for measuring Health-Related Quality of Life among prostate cancer survivors. UROLOGY, 2010 Mar 27. [Epub ahead of print] PubMed PMID: 20350762.

Bhatt RS, Werner L, Regan MM, Yannucci J, Wang HY, Rosen S, Genega E, Morrissey ME, Duggan S, Vazquez C, Sanda MG, DeWolf W, Balk S, Yuan X, Bubley GJ.  Possible risk factors associated with relapse in patients treated with neoadjuvant chemohormonal therapy for high risk prostate cancer. OPEN PROSTATE CA JOURNAL, accepted for publication.

Hayn MH, Orom H, Shavers VL, Sanda MG, Glasgow M, Mohler JL, Underwood W. Racial/Ethnic Differences in Receipt of Pelvic Lymph Node Dissection among Men with Localized/Regional Prostate Cancer.  CANCER, Oct 15 2011 Volume: 117(20): 4651-4658.

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RHN, Mizrahi IA. A Multi-Center Study of [-2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. J UROLOGY, 2011 May;185(5):1650-5. Epub 2011 Mar 17. PMID: 21419439.

Kamo N, Dandapani SV, Miksad RA, Houlihan MJ, Kaplan I, Regan M, Greenfield TK, Sanda MG. Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet. ANN ONCOL. 2011 Mar; 22(3):723-9. Epub 2010 Aug 17. PMID: 20716625.

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM,* Rubin MA,* Sanda MG.* Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2011 May 19. [Epub ahead of print] PubMed PMID: 21600800.

Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WS, Bubley GJ, Funches R, Aronovitz JA, Wei JT,* and Sanda MG.* Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): Development and Validation of a Practical Health-Related Quality of Life Instrument for Use in the Routine Clinical Care of Prostate Cancer Patients.  JOURNAL OF UROLOGY, 2011 Sep;186(3):865-72. Epub 2011 Jul 23. PubMed PMID: 21788038.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. SCIENCE TRANSL MED. 2011 Aug 3; 3(94):94ra72. PubMed PMID: 21813756.

Kasperzyk JL, Shappley WV 3rd, Kenfield SA, Mucci LA, Kurth T, Ma J, Stampfer MJ, Sanda MG. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol. 2011 Nov;186(5):1862-7. Epub 2011 Sep 23. PubMed PMID: 21944095.

Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, and Sanda MG. Prediction of Erectile Function Following Treatment for Prostate Cancer. JAMA, 2011 Sep 21; 306(11):1205-14. PMID:21934053.

Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG, Dewolf WC, Rofsky NM. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. EUR RADIOL. 2012 Jun 3. [Epub ahead of print] PubMed PMID: 22661019.

Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer. BIOM J. 2012 Jan;54(1):127-42. doi: 10.1002/bimj.201100062. Epub 2011 Nov 17. PubMed PMID: 22095849.

Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon A, Suppan C, Flavin R, Sesso H, Rider JR, Sweeney CS, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci E, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis. CANCER EPIDEMIOL BIOMARKERS PREV. 2012 Jun 26. [Epub ahead of print] PubMed PMID: 22736790.

Kim SB, Williams SB, Cheng SC, Sanda MG, Wagner AA. Evaluation of Patient-reported Quality-of-life Outcomes After Renal Surgery. UROLOGY. 2012 Jun;79(6):1268-73. Epub 2012 Apr 28. PubMed PMID: 22542421; PubMed Central PMCID: PMC3367127.

Harden JK, Sanda MG, Wei JT, Yarandi H, Hembroff L, Hardy J, Northouse LL; PROSTQA Consortium Study Group. Partners' Long-term Appraisal of Their Caregiving Experience, Marital Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment. CANCER NURS. 2012 Jun 21. [Epub ahead of print] PubMed PMID: 22728952.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnaiyan AM, Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT, Scherr DS, Sanda MG, Bartsch G, Lee C, Klocker H, Rubin MA. Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. PROC NATL ACAD SCI U S A. 2012 Apr 24;109(17):6686-91. Epub 2012 Apr 10. PubMed PMID: 22496589; PubMed Central PMCID: PMC3340033.

Lu B, Asara JM, Sanda MG, Arredouani MS. The role of the transcription factor SIM2 in prostate cancer. PLOS ONE. 2011;6(12):e28837. Epub 2011 Dec 9. PubMed PMID: 22174909; PubMed Central PMCID: PMC3235151.

Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. CANCER. 2012 May 15;118 (10):2651-8. doi: 10.1002/cncr.26396. Epub 2011 Oct 17. PubMed PMID: 22006057.